Blue Trust Inc’s Aurinia Pharmaceuticals AUPH Stock Holding History

Blue Trust Inc’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.7K	Hold	690	–	–	﹤0.01%	1821
2026 Q1	$10.2K	Sell	690 -1,431	-67%	-$20.9K	﹤0.01%	1837
2025 Q4	$33.8K	Sell	2,121 -4,455	-68%	-$63.2K	﹤0.01%	1491
2025 Q3	$72.7K	Hold	6,576	–	–	﹤0.01%	1221
2025 Q2	$55.7K	Sell	6,576 -603	-8%	-$4.83K	﹤0.01%	1412
2025 Q1	$57.7K	Buy	7,179 +802	+13%	+$6.5K	﹤0.01%	1266
2024 Q4	$57.3K	Buy	6,377 +6,174	+3,041%	+$50.4K	﹤0.01%	1230
2024 Q3	$1.16K	Buy	+203	New	+$1.26K	﹤0.01%	2681
2024 Q1	–	Sell	-55	Closed	–	–	2193
2023 Q4	$0	Buy	+55	New	+$453	﹤0.01%	2480
2023 Q1	–	Sell	-27	Closed	–	–	2297
2022 Q4	$0	Buy	+27	New	+$157	﹤0.01%	2224

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Blue Trust Inc's AUPH Position: Q2 2026 in Review

Blue Trust Inc held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2026 at 690 shares worth $11.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1821.

Blue Trust Inc first reported a position in AUPH in Q4 2022 and has held it in 10 quarters since. The position peaked at $72.7K in Q3 2025. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Blue Trust Inc held 690 shares of Aurinia Pharmaceuticals worth $11.7K as of Q2 2026.
Blue Trust Inc left its Aurinia Pharmaceuticals share count unchanged in Q2 2026.
Aurinia Pharmaceuticals made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #1821 holding.
Blue Trust Inc first reported a position in Aurinia Pharmaceuticals in Q4 2022 and has held it in 10 quarters since.
Blue Trust Inc's Aurinia Pharmaceuticals position peaked at $72.7K in Q3 2025.
282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.